Media release
Toll Healthcare expands partnership with CSL Seqirus with new Tullamarine warehouse
Toll Group has announced the construction of a new, 10,000 sqm state-of-the-art healthcare facility at Tullamarine, near Melbourne. Toll is a leading supply chain partner to CSL Seqirus, and the facility is being custom built to support CSL Seqirus’ operations.
The warehouse and distribution centre will be situated next to the future CSL Seqirus manufacturing site, bolstering Toll's tailored support for CSL Seqirus by handling both finished goods distribution and supplying raw materials and packaging to the CSL Seqirus manufacturing facility.
Toll’s warehouse and distribution centre is due to commence operations in August 2024.
The new warehouse marks Toll's commitment to providing comprehensive logistics solutions for the healthcare sector. With operations commencing in Tullamarine, Toll aims to enhance efficiency and timeliness through just-in-time services. The collaboration between Toll and CSL Seqirus underscores a shared dedication to innovation and excellence in healthcare logistics.
"We are proud to strengthen our partnership with CSL Seqirus and expand our footprint in the healthcare logistics sector," said Perry Singh, President, Government & Defence at Toll.
"This new facility exemplifies our commitment to delivering high-quality, tailored supply chain solutions to meet the evolving needs of our customers."
In addition to the Tullamarine facility, in April 2023 Toll opened new warehouse in Richlands, Queensland, further demonstrating its dedication to enhancing healthcare logistics infrastructure across Australia.
“The facilities are part of Toll’s broader multi-million-dollar investment creating advanced warehouse management solutions to meet the changing dynamics in the healthcare sector, and providing customers with the logistical support they need,” Mr. Singh said.
Toll’s facility will be situated adjacent to the soon-to-be-completed CSL Seqirus plant, a new world-class biotech manufacturing facility in Australia which will supply influenza vaccines to Australia and the rest of the world. The state-of-the-art facility will use innovative cell-based technology to produce influenza vaccines for use in both influenza pandemics and seasonal vaccination programs – and will be the only cell-based influenza vaccine manufacturing facility in the Southern Hemisphere.
-ENDS-
For media inquiries, please contact:
[email protected]
About Toll Healthcare
Toll Healthcare provides integrated logistics solutions for the storage and distribution of pharmaceutical and surgical products across Australia, delivering comprehensive supply chain solutions tailored to the healthcare sector's unique requirements.
Annually, Toll completes over 100,000 deliveries of temperature-sensitive, time-critical, and high-value pharmaceutical products, including vaccines and life-saving anti-venoms, to hospitals, medical clinicians, pharmacies, and patients nationwide. Operating from TGA-licensed warehouses in Sydney, Melbourne, Brisbane, Adelaide, and Perth, Toll Healthcare ensures distribution reaches even the most remote areas of Australia.
About Toll Group
At Toll Group, we do more than just logistics-we move the businesses that move the world. Our 16,000+ team members can help solve any logistics, transport or supply chain challenge – big or small. We have been supporting our customers for more than 130 years. Today, we support more than 20,000 customers worldwide with 500 sites in 27 markets, and a forwarding network spanning 150 countries. We are proudly part of Japan Post.
